21 May 2013
Keywords: OXiGENE, VaxGen, M&A, Research refoscusing, Zybrestat, Macular degeneration
Article | 15 February 2010
US cancer and eye disease drug developer OXiGENE has revealed a restructuring plan designed to focus resources on the company's ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 February 2010
16 February 2010
20 May 2013
© 2013 thepharmaletter.com